Seladelpar

Drug Profile

Seladelpar

Alternative Names: MBX 8025; RWJ 800025

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Ortho-McNeil
  • Developer CymaBay Therapeutics
  • Class Acetates; Triazoles
  • Mechanism of Action C-reactive protein inhibitors; Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type V; Hyperlipoproteinaemia type I; Hyperlipoproteinaemia type IIa; Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperlipidaemia; Hyperlipoproteinaemia type IIa; Primary biliary cirrhosis
  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 23 Mar 2017 CymaBay Therapeutics has patents pending for seladelpar
  • 01 Dec 2016 CymaBay Therapeutics initiates a phase II trial for Primary biliary cirrhosis (Treatment experienced) in Germany after December 2016 (PO, Capsule) (NCT02955602)
  • 11 Nov 2016 Pharmacodynamics data from a preclinical study in Non-alcoholic steatohepatitis presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top